Diabetic Macular Oedema Clinical Trial
Official title:
Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema (DMO)- Randomized Controlled Trial
NCT number | NCT02457884 |
Other study ID # | 12131601 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2015 |
Est. completion date | June 2018 |
Verified date | February 2019 |
Source | The Hong Kong Polytechnic University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Diabetic macular oedema (DMO) is a sight-threatening problem for diabetic patient who has
swelling in macula. Patients with DMO can receive laser treatment and achieve good acuity
finally. However, some patients still have difficulties in reading even after proper
treatment.
In this project, the investigators aimed to explore the effectiveness of different training
paradigms in improving reading performance in patients with DMO.
Status | Completed |
Enrollment | 55 |
Est. completion date | June 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Able to read Chinese. - No formal vision rehabilitation training in reading after vision loss - Diagnosis of diabetic macular oedema (DMO) and had previous treatment with laser and / or intravitreal injections - Reasonable control of blood glucose level (HbA1c <10) to minimize the impact of vision fluctuation - Education level of 6 years or more (primary school or above) Exclusion Criteria: - Receive any types of eye treatments other than those mentioned above - Any diagnosed ocular diseases other than DMO - Severe medical problems or self reported neurological or cognitive disorders - Serious hearing impairment - Previously attended vision rehabilitation clinic |
Country | Name | City | State |
---|---|---|---|
China | Allen MY Cheong | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The Hong Kong Polytechnic University | The University of Hong Kong |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in visual processing speed | Using trigrams to measure the character-recognition accuracy while characters are presented at different exposure times | Change from baseline at week 6 and change from baseline at week 12 week | |
Primary | Change in visual span size | Using trigrams to measure the character-recognition accuracy while characters are presented at different positions | Change from baseline at week 6 and change from baseline at week 12 week | |
Secondary | Change in reading performance | Measured in three different ways for Chinese: Rapid serial visual presentation (RSVP) Sentence reading (MNREAD) Passage reading (IReST) |
Change from baseline at week 6 and change from baseline at week 12 week | |
Secondary | Change in fixation stability | Fixation stability will be measured by MP-1 microperimeter. | Change from baseline at week 6 and change from baseline at week 12 week | |
Secondary | Change in Chinese version of Impact of Visually Impaired (C-IVI) measure | Self evaluated instrument to measure vision related restriction of participation in daily living. | Change from baseline at week 6 and change from baseline at week 12 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04576689 -
Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy
|
Phase 2 | |
Completed |
NCT02554747 -
Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa
|
N/A | |
Withdrawn |
NCT02309476 -
Sub-threshold Photocoagulation of Diabetic Macular Oedema
|
N/A | |
Terminated |
NCT02207712 -
Noctura400 Treatment for Diabetic Retinopathy (CANDLE)
|
N/A | |
Completed |
NCT00148330 -
Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study
|
Phase 2/Phase 3 | |
Completed |
NCT03495765 -
To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00167518 -
Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)
|
Phase 2/Phase 3 | |
Completed |
NCT01787669 -
Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
|
Phase 2 | |
Completed |
NCT01175070 -
Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
|
Phase 4 | |
Terminated |
NCT00427986 -
Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema
|
N/A | |
Completed |
NCT00333671 -
Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema)
|
N/A | |
Completed |
NCT02731911 -
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
|
||
Completed |
NCT00148265 -
A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema
|
Phase 2/Phase 3 | |
Completed |
NCT02181400 -
Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema
|
N/A |